Research indicates that many common medications used by millions of Americans can have long-term effects on the body, even after they’ve been discontinued.
Beta-blockers, which are often prescribed for heart issues and high blood pressure, were found to alter gut bacteria, and these changes persisted even years after patients stopped using them, as reported by researchers from Estonia.
This pattern was also observed with anti-anxiety medications such as Xanax and Valium, as well as antidepressants and proton pump inhibitors, which are frequently used to treat acid reflux and heartburn.
The microbiome, a collection of beneficial bacteria in the body, plays a crucial role in health by helping to fight illnesses, absorbing nutrients, and regulating immune and metabolic systems. Its diversity is essential and can be impacted by a variety of factors, including diet and medications.
The study highlights that medications—ranging from antibiotics to antidepressants—can significantly reduce the diversity of gut bacteria, effects that may last for years.
Lesser diversity in the microbiome is linked to a weakened gut barrier, chronic inflammation, and compromised immune responses. This condition, known as dysbiosis, is associated with an increased risk of developing conditions like colorectal cancer.
Dysbiosis favors the growth of bacteria that can promote cancer, potentially leading to tumor growth by encouraging blood vessel formation and cell division.
To explore the long-lasting impact of drugs on gut bacteria, researchers analyzed stool samples from over 2,500 adults. Follow-up samples from a smaller group four years later, along with prescription records, shed light on the effects of medications including acid reflux drugs, antidepressants, and anxiety treatments.
Of the 186 medications evaluated, 90% disrupted the microbiome, with many—like antibiotics, antidepressants, and proton pump inhibitors—showing persistent effects for more than three years.
Antibiotics, such as azithromycin and penicillin, were particularly damaging to the microbiome, with effects detectable for over three years. The lack of recovery in bacterial diversity suggests that this damage might be lasting.
Similarly, benzodiazepines were linked to a reduced variety of gut bacteria, and their effects were cumulative over time, leading to increased gut imbalances.
Beta-blockers were identified as one of the most significant disruptors of gut health, causing substantial variations in gut bacteria.
Proton pump inhibitors also had long-term negative effects, diminishing diversity and fostering a pro-inflammatory state that could contribute to cancer. These alterations to the gut’s microbial ecosystem were evident even years after cessation of treatment.
Additionally, a dysbiotic gut may lead to a ‘leaky’ barrier, which allows bacteria and toxins to enter the bloodstream, creating a chronic state of low-level inflammation throughout the body.
A microbiome with reduced diversity is less effective at detoxifying harmful substances and produces fewer protective molecules like butyrate, which increases vulnerability to factors that can damage DNA and potentially initiate cancer development.
Recent research established that changes in gut bacteria, including the rise of harmful strains, are tied to a significant percentage of colorectal cancer cases.
This research demonstrated that these newly identified bacteria can actually trigger the development of precancerous growths in the colon. Changes in the microbiome can also create an environment conducive to precancerous conditions by affecting the cells critical for maintaining tissue integrity.
Dr. Oliver Aasmets, from the University of Tartu Institute of Genomics and lead author of the study, noted that many microbiome studies focus on current medication use. However, their results suggest that past medication use is also crucial in understanding variations in individual microbiomes.
These findings, published in the journal mSystems, could impact millions of Americans. In the U.S., healthcare providers prescribed roughly 270 million antibiotics annually.
It’s noted that about 30 million individuals use benzodiazepines, an equal number takes beta-blockers, and approximately 30 million are on SSRIs.
